Palvella Therapeutics (PVLA) Receivables (2013 - 2024)
Palvella Therapeutics (PVLA) posted quarterly Receivables of $358000.0 for Q4 2024, down 84.61% year-over-year from $2.3 million in Q1 2024, and down 59.27% quarter-over-quarter from $879000.0 in Q3 2024.
Palvella Therapeutics (PVLA) Receivables (2013 - 2024) Analysis & Trends
Palvella Therapeutics (PVLA) has reported Receivables for 12 consecutive years, with $358000.0 the latest figure, recorded in Q4 2024.
- In Q4 2024, Receivables fell 84.61% year-over-year to $358000.0; the TTM figure through Dec 2024 stood at $358000.0 (down 84.61% YoY), while the FY2024 annual figure was $358000.0, down 84.61% from the prior year.
- Receivables fell to $358000.0 in Q4 2024 per PVLA's latest filing, from $879000.0 in the prior quarter.
- Across five years, Receivables topped out at $15.8 million in Q1 2021 and bottomed at $358000.0 in Q4 2024.
- Historically, Receivables has averaged $3.7 million across 5 years, with a median of $2.0 million in 2020.
- Annual changes were most pronounced in 2022 — Receivables sank 89.6% — and 2024, when it surged 295.64%.
- Palvella Therapeutics' Receivables stood at $1.7 million in 2020, then jumped by 94.2% to $3.3 million in 2021, then surged by 89.31% to $6.3 million in 2022, then sank by 62.91% to $2.3 million in 2023, then slumped by 84.61% to $358000.0 in 2024.
- Business Quant data shows PVLA's Receivables at $358000.0 in Q4 2024, $879000.0 in Q3 2024, and $1.6 million in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.13 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 6.57 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.93 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.06 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1.84 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 912.74 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 215.33 Mn |
| 10 | Palvella Therapeutics | 2.25 Bn | 1.93 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 358,000.00 |
| Sep 30, 2024 | 879,000.00 |
| Jun 30, 2024 | 1.62 Mn |
| Mar 31, 2024 | 4.17 Mn |
| Dec 31, 2023 | 2.33 Mn |
| Sep 30, 2023 | 1.05 Mn |
| Jun 30, 2023 | 952,000.00 |
| Mar 31, 2023 | 1.06 Mn |
| Dec 31, 2022 | 6.27 Mn |
| Sep 30, 2022 | 829,000.00 |
| Jun 30, 2022 | 1.26 Mn |
| Mar 31, 2022 | 1.64 Mn |
| Dec 31, 2021 | 3.31 Mn |
| Sep 30, 2021 | 6.65 Mn |
| Jun 30, 2021 | 2.80 Mn |
| Mar 31, 2021 | 15.81 Mn |
| Dec 31, 2020 | 1.71 Mn |
| Sep 30, 2020 | 2.94 Mn |
| Jun 30, 2020 | 10.71 Mn |
| Mar 31, 2020 | 7.27 Mn |